Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy

Altman, 1993, Chromic leukemias of childhood, 501 Altman, 1974, Juvenile ‘chronic granulocytic leukemia’: A panmyelopathy with prominent monocytic involvement and circulating monocyte colony-forming cells, Blood, 43, 341, 10.1182/blood.V43.3.341.341 Castro-Malaspina, 1984, Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors, Cancer, 54, 675, 10.1002/1097-0142(1984)54:4<675::AID-CNCR2820540415>3.0.CO;2-Q Estrov, 1986, Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures, Blood, 67, 1382, 10.1182/blood.V67.5.1382.1382 Luna-Fineman, 1995, Childhood monosomy 7: epidemiology, biology and mechanistic implications, Blood, 85, 1985, 10.1182/blood.V85.8.1985.bloodjournal8581985 Herrod, 1983, Persistent Epstein-Barr virus infection mimicking juvenile chronic myelogenous leukemia: immunologic and hematologic studies, Blood, 61, 1098, 10.1182/blood.V61.6.1098.1098 Kirby, 1990, Juvenile chronic myelogenous leukemia: differentiation from infantile cytomegalovirus infection, Am. J. Pediatr. Hematol. Oncol., 12, 292, 10.1097/00043426-199023000-00007 Busque, 1995, Clonality in juvenile chronic myelogenous leukemia, Blood, 85, 21, 10.1182/blood.V85.1.21.bloodjournal85121 Bagby, 1988, Interleukin 1-dependent paracrine granulopoiesis in chronic granulocytic leukemia of the juvenile type, J. Clin. Invest., 82, 143, 10.1172/JCI113748 Freedman, 1992, Central role of tumor necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogeneous leukemia, Br. J. Haematol., 80, 40, 10.1111/j.1365-2141.1992.tb06398.x Emanuel, 1991, The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia, Exp. Hematol., 19, 1017 Emanuel, 1991, Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors, Blood, 77, 925, 10.1182/blood.V77.5.925.925 Lapidot, 1993, Aberrant growth properties of juvenile chronic myelogeneous leukemia (JCML) CD34+ cells in vitro and in vivo using SCID mouse assays, Blood, 82, 197a Cambier, 1995, GM-CSF hypersensitivity in CD34+ purified cells in juvenile and adult chronic myelomonocytic leukemia: effect of retinoids, Blood, 86, 791a Wagner, 1992, Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment, Blood, 79, 1874, 10.1182/blood.V79.7.1874.1874 Prchal, 1974, Bone-marrow responses in polycythemia vera, New Engl. J. Med., 290, 1382, 10.1056/NEJM197406132902419 Dai, 1991, Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3, J. Clin. Invest., 87, 391, 10.1172/JCI115009 Correa, 1994, Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium, Blood, 83, 99, 10.1182/blood.V83.1.99.99 Prchal, 1985, Autosomal dominant polycythemia, Blood, 66, 1208, 10.1182/blood.V66.5.1208.1208 Emanuel, 1991, Hypersensitivity to hemopoietic growth factors in chronic myelomonocytic leukemia (CMML), Blood, 78, 156a Li, 1995, Spontaneous CFU-MK formation in essential thrombocythemia (ET) is not due to autocrine TPO secretion and disappears with cellular dilution and use of selected CD34+ cells, Blood, 86, 48a Taylor, 1995, Inappropriate elevation and loss of feedback regulation of thrombopoietin in essential thrombocythaemia (ET), Blood, 86, 49a Prchal, 1994, Evolving understanding of the cellular defect in polycythemia vera: implications for its clinical diagnosis and molecular pathophysiology, Blood, 83, 1, 10.1182/blood.V83.1.1.1 Bourne, 1990, The GTPase superfamily: a conserved switch for diverse cell functions, Nature, 348, 125, 10.1038/348125a0 Satoh, 1991, Involvement of ras p21 protein in signal transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4, 88, 3314 Bos, 1989, ras oncogenes in human cancer: a review, Cancer Res., 49, 4682 Miyauchi, 1994, Mutations of the N-ras gene in juvenile chronic myelogeneous leukemia, Blood, 83, 2248, 10.1182/blood.V83.8.2248.2248 Boguski, 1993, Proteins regulating Ras and its relatives, Nature, 366, 643, 10.1038/366643a0 Bader, 1978, Neurofibromatosis and childhood leukemias, J. Pediatr., 92, 925, 10.1016/S0022-3476(78)80362-X Kalra, 1994, Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras, Blood, 84, 3435, 10.1182/blood.V84.10.3435.3435 Brodeur, 1994, The NF1 gene in myelopolesis and childhood myelodysplastic sydromes, New Engl. J. Med., 330, 637, 10.1056/NEJM199403033300912 Shannon, 1994, Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders, New Engl. J. Med., 330, 597, 10.1056/NEJM199403033300903 Bollag, 1996, Loss of NF1 results in activation of the Ras signalling pathway and leads to aberrant growth in haematopoietic cells, Nat. Genet., 12, 144, 10.1038/ng0296-144 Largaespada, 1996, Nf1 deficiency causes Ras mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia, Natur. Genet., 12, 137, 10.1038/ng0296-137 Lilleyman, 1977, Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine, Blood, 49, 559, 10.1182/blood.V49.4.559.559 Chan, 1987, The value of intensive combination chemotherapy for juvenile chronic myelogeneous leukemia, J. Clin. Oncol., 5, 1960, 10.1200/JCO.1987.5.12.1960 Smith, 1994, Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia, Blood, 84, 201a Passmore, 1995, Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system, Blood, 85, 1742, 10.1182/blood.V85.7.1742.bloodjournal8571742 Castleberry, 1994, A pilot study of isoretinoin in the treatment of juvenile chronic myelogenous leukemia, New Engl. J. Med., 331, 1680, 10.1056/NEJM199412223312503 Gibbs, 1994, Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic, Cell, 77, 175, 10.1016/0092-8674(94)90308-5